MS patients
Incidence rates of MS
main shortcoming of current MS treatments
treatment of
Europe
class multiple sclerosis drug Multiple sclerosis
current treatment options
progressive neurodegenerative disease
progressive neurodegeneration
number of patients
young people
Canada
US
inconvenient administration routes
UK
cancer
Spain
high costs
Italy
Germany
France
major markets
increased risks of infection
severe side-effects
Japan
society
significant economic burden
market value
projected sales
China
regions
small molecule
limited efficacies
commercial viability
approved drugs
India
GlobalData
northern hemisphere
Commercialization
lack of efficacy
aim of DIDO
productive years